ライフサイエンスコーパス: premature delivery

1 ral complications, including miscarriage and premature delivery.

2 m neurocognitive impairments associated with premature delivery.

3 cts, preeclampsia, spontaneous abortion, and premature delivery.

4 ECE-1/ET-1 system in inflammation-associated premature delivery.

5 spina bifida, but increases the incidence of premature delivery.

6 rth weight, low birth-weight percentile, and premature delivery.

7 omplication of pregnancy with no cure except premature delivery.

8 omes, and the secondary outcome variable was premature delivery.

9 se pregnancy outcomes, such as stillbirth or premature delivery.

10 the pathogenesis of inflammation-associated premature delivery.

11 There were 11 miscarriages (9%), 4 premature deliveries (3%), and 1 early neonatal death; 3

12 table gastric band surgery (7.7% vs 7.1% for premature delivery; 7.7% vs 10.6% for low birth weight,

13 e associated with a 572% increase in odds of premature delivery (adjusted odds ratio, 6.72; 95% CI, 2

14 with maternal anemia, low birth weight, and premature delivery and can lead to the death of mother a

15 are administered to human fetuses at risk of premature delivery and to infants with life-threatening

16 parasitemia and associated maternal anemia, premature delivery, and low birth weight.

17 was not associated with an increased risk of premature delivery as compared with monotherapy (odds ra

18 l period was 36.4+/-3.2 weeks, excluding two premature deliveries at 23 and 24 weeks gestation.

19 The ability to control premature delivery by antagonizing or silencing the ECE-

20 inally, we show here for the first time that premature delivery can be controlled using RNA silencing

21 version of androgen to estrogen and prevents premature delivery caused by administration of androgen

22 s in obstetrics and neonatology, the rate of premature delivery has increased approximately 12% since

23 ney disease characterized by polyhydramnios, premature delivery, hypokalemic alkalosis and hypercalci

24 antagonist synthesized by our group, control premature delivery in a mouse model of inflammation-asso

25 ring pregnancy that often leads to abortion, premature delivery, intrauterine growth restriction and

26 We also show that premature delivery is controlled by treatment with the s

27 he role of the cervix in the pathogenesis of premature delivery is controversial.

28 cco, alcohol, and illicit drugs, the rate of premature delivery (<37 weeks of gestation) was similar

29 nd alteration in its normal signaling during premature delivery might explain the pathophysiology of

30 Premature delivery occurs in 12% of all births and accou

31 Premature delivery occurs in 12% of all births, and acco

32 segregation of EGFR from early endosomes and premature delivery of EGFR to the late endosomal and lys

33 mpanies neonatal stress in scenarios such as premature delivery or intrauterine growth restriction.

34 en is not associated with increased rates of premature delivery or with low birth weight, low Apgar s

35 ese controls (26.3%-26.9% vs 22.4%-20.2% for premature delivery, P = not reported [1 study] and P = .

36 ring the third trimester had higher rates of premature delivery (relative risk, 4.8; 95 percent confi

37 Premature delivery should be avoided whenever possible.

38 The injection resulted in premature delivery, stillbirths, and nonsustained live b

39 oids are given to pregnant women at risk for premature delivery to promote lung maturation.

40 ta901 to be misfolded, however, resulting in premature delivery to the vacuole for degradation.

41 In addition, the frequency of premature delivery was higher in group 2 (37 percent vs.

42 Adverse pregnancy outcomes and premature delivery were defined using International Clas